Concepedia

Manoj A. Jivani

MA

4

Publications

70

Citations

4

H-Index

2015

Active since

Affiliations

Tracon Pharmaceuticals (United States)(Current)

Roswell Park Comprehensive Cancer Center

Beth Israel Deaconess Medical Center

Cedars-Sinai Medical Center

University of Alabama at Birmingham

Manoj A. Jivani is an author at Tracon Pharmaceuticals (United States) specializing in tumor immunity, tumor biology, and cancer therapeutics.

Top concepts

Publications per year

2015–2020

4

Publications

4

An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma

Toni K. Choueiri, M. Dror Michaelson, Edwin M. Posadas et al. · The Oncologist · 2018 · 29 citations · Full text

ENGINE: A Phase III Randomized Placebo Controlled Study of Enzastaurin/R-CHOP as Frontline Therapy in High-Risk Diffuse Large B-Cell Lymphoma Patients with the Genomic Biomarker DGM1

Grzegorz S. Nowakowski, Jun Zhu, Qingyuan Zhang et al. · Future Oncology · 2020 · 20 citations · Full text

A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma.

Toni K. Choueiri, M. Dror Michaelson, Edwin M. Posadas et al. · Journal of Clinical Oncology · 2015 · 11 citations

, , +17

A phase 2 trial of TRC105 with bevacizumab for bevacizumab refractory glioblastoma.

Manmeet S. Ahluwalia, Lisa R. Rogers, Rekha Chaudhary et al. · Journal of Clinical Oncology · 2016 · 10 citations

, , +20

Rows per page

1–4 of 4